Lucy Vereshchagina, PhD
Dr. Lucy Vereshchagina is executive vice president of science and regulatory advocacy at PhRMA. In this role, Dr. Vereshchagina leads PhRMA’s science and regulatory advocacy department supporting PhRMA’s policy, advocacy and science priorities, as well as global regulatory advocacy efforts, including the International Council for Harmonization (ICH). Dr. Vereshchagina was the lead PhRMA negotiator for both PDUFA VII and BsUFA III and testified before Congress on the agreements’ reauthorization.
Prior to joining PhRMA in 2012, Dr. Vereshchagina spent over 12 years with the FDA & Healthcare Practice at an international law firm and the Investigational Drug Branch at the National Cancer Institute. She has a master’s degree in Biochemistry and Chemistry, earned her Ph.D. in Chemistry at the Catholic University of America, and completed her post-doctoral studies in molecular biology and immunology at the Walter Reed Army Institute of Research.
Executive Vice President of Science and Regulatory Advocacy
https://www.linkedin.com/in/lucy-vereshchagina-phd-416b27a/
PDUFA creates an efficient drug review process that benefits American patients
PDUFA: Essential to America’s edge in drug development and patient access
4 things to know on Rare Disease Day
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
Three things to know about the accelerated approval pathway
The importance of timely PDUFA and BsUFA reauthorization
New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
Lucy Vereshchagina